Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,588 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cns Cancer Clear all
Recruiting Not applicable Interventional

PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial

NCT06397560
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Recurrent Glioma
Interventions
PRDR
Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boca Raton, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas

NCT04264143
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas, Diffuse Midline Glioma
Interventions
Infusate with MTX110 and gadolinium, Convection-Enhanced Delivery (CED)
Drug · Device
Lead sponsor
Luca Szalontay
Other
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Jun 27, 2026, 9:27 PM EDT
Terminated Not applicable Interventional Results available

Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

NCT00582608
View directory record Official record
Conditions
CNS Cancer, Neuroblastoma, Sarcoma
Interventions
131I-8H9, 8H9
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

NCT00301418
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Erlotinib
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Jun 27, 2026, 9:27 PM EDT
Completed No phase listed Observational

Study of the Health Information Needs of Brain Cancer Patients

NCT01130220
View directory record Official record
Conditions
Brain Tumor
Interventions
Focus Group
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma

NCT01480050
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care

NCT04916223
View directory record Official record
Conditions
Cancer, Heart Failure, COPD, Sepsis, HIV Infections, ESRD, Trauma, Stroke
Interventions
Therapeutic massage
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Sunitinib in Treating Young Patients With Refractory Solid Tumors

NCT00387920
View directory record Official record
Conditions
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Jun 27, 2026, 9:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neurocognitive Decline in Patients With Brain Metastases

NCT03508752
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional

Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors

NCT00110032
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Central Nervous System Germ Cell Tumor, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma
Interventions
EF5, conventional surgery, positron emission tomography, fluorine F 18 EF5, pharmacological study
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

NCT00082836
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

NCT00000801
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Filgrastim, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Cytarabine, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Recurrent High-Grade Glioma

NCT00619112
View directory record Official record
Conditions
Recurrent Central Nervous System Neoplasm
Interventions
temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jun 27, 2026, 9:27 PM EDT
Active, not recruiting Not applicable Interventional

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

NCT03033992
View directory record Official record
Conditions
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Interventions
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Concurrent Optune and RT followed by Optune System alone
Device · Combination Product
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Completed No phase listed Observational

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

NCT03194971
View directory record Official record
Conditions
Glioblastoma
Interventions
Tumor samples from patients treated with TTFields at initial diagnosis., Tumor samples from patients treated with TTFields at tumor recurrence.
Other · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT06333899
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
Interventions
Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional

Procarbazine in Treating Patients With Recurrent Brain Tumor

NCT00004004
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
procarbazine hydrochloride
Drug
Lead sponsor
New Approaches to Brain Tumor Therapy Consortium
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 27, 2026, 9:27 PM EDT
Active, not recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

NCT02574728
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Completed No phase listed Observational

Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS

NCT02603692
View directory record Official record
Conditions
Brain Neoplasms
Interventions
PROMIS-QOL
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jun 27, 2026, 9:27 PM EDT
Completed No phase listed Observational

Cognitive Function After Treatment of Primary CNS Malignancy

NCT03055364
View directory record Official record
Conditions
CNS Malignancy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jun 27, 2026, 9:27 PM EDT
Completed No phase listed Observational

Evaluation of Factors in Human Brain Tumors

NCT00001171
View directory record Official record
Conditions
Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1979 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
View directory record Official record
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Jun 27, 2026, 9:27 PM EDT
Terminated Phase 2 Interventional Results available

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

NCT05746481
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 27, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors

NCT00002472
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Pediatric Germ Cell Tumor, Extragonadal Germ Cell Tumor
Interventions
cisplatin, etoposide, conventional surgery, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Jun 27, 2026, 9:27 PM EDT